CYTOMAC Cytokine signaling in macrophages: beyond JAK-STAT
- Coordinator
- Stichting Amsterdam Umc, Netherlands
- Runs
- 1 September 2023 to 31 August 2028
- Status
- Running
- EU funding
- €1.5m
- Total cost
- €1.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101076170
What the project is doing
In the project's own words, from its summary on CORDIS.
Dysregulated macrophage function underlies many inflammatory diseases. Cytokines, small secreted signaling molecules with immune-modulatory functions, shape the macrophage’s phenotype, thereby affecting disease states. Puzzlingly, many cytokines with opposing functions, utilize highly similar JAK-STAT signaling cascades, leaving it unclear how cytokine-specific responses can occur. In my previous work, I studied enhancer activation in mouse macrophages from genetically different strains.
By studying genetic variation, I found that transcription factor (TF) motifs crucial for enhancer activation can be identified. I further developed the bio-informatic tool MAGGIE to study TF motif mutations in different strains of mice, which subsequently enabled me to discover a novel TF important for enhancer activation by the cytokine interleukin-4. Based on my findings, I hypothesize that cytokines require specific, yet unidentified TFs that cooperate with JAK-STAT signaling to mount cytokine-specific effects.
CYTOMAC aims to identify these cytokine-specific TFs downstream of JAK-STAT that direct appropriate cell responses. I will exploit the genetic variation across mouse strains and study enhancer activation in macrophages from these strains in response to different disease-related cytokines. Specifically, I will: (1) use genetic diversity between mouse strains to identify specific TFs regulating cytokine-specific responses; to then target these novel TFs in (2) mouse and (3) human macrophages and (4) translate my findings to human disease and inflammatory disease models.
Inhibitors targeting JAK-STAT show high potential in clinically treating inflammatory diseases, including rheumatoid arthritis. However, as they affect generic pathways of many cytokines they come with considerable side-effects, limiting applicability. CYTOMAC will reveal novel, cytokine-specific TFs, which will aid in developing better tailored intervention strategies.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI